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ABSTRACT 
Purpose To develop quercetin-loaded phospholipid vesicles, namely liposomes and PEVs 
(Penetration Enhancer-containing Vesicles), and to investigate their efficacy on TPA-induced skin 
inflammation. 
Methods Vesicles were made from a mixture of phospholipids, quercetin and polyethylene glycol 
400 (PEG), specifically added to increase drug solubility and penetration through the skin. Vesicle 
morphology and self-assembly were probed by Cryo-Transmission Electron Microscopy and 
Small/Wide Angle X-ray Scattering, as well as the main physico-chemical features by Light 
Scattering. 
The anti-inflammatory efficacy of quercetin nanovesicles was assessed in vivo on TPA-treated mice 
dorsal skin by the determination of two biomarkers: oedema formation and myeloperoxidase 
activity. The uptake of vesicles by 3T3 fibroblasts was also evaluated. 
Results Small spherical vesicles were produced. Their size and lamellarity was strongly influenced 
by the PEG content (0%, 5%, 10% v/v). The administration of vesicular quercetin on TPA-inflamed 
skin resulted in an amelioration of the tissue damage, with a noticeable attenuation of oedema and 
leukocyte infiltration, especially using 5% PEG-PEVs, as also confirmed by confocal microscopy. 
In vitro studies disclosed a massive uptake and diffusion of PEVs in dermal fibroblasts. 
Conclusions The proposed approach based on quercetin vesicular formulations may be of value in 
the treatment of inflammatory skin disorders. 
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INTRODUCTION 
During last years there has been a great scientific interest in the use of phytodrugs from plant foods 
to treat inflammation, which is responsible for chronic wounds and cancer. In particular, dietary 
polyphenols are being extensively studied for their striking antioxidant, anti-inflammatory, 
chemopreventive and chemotherapeutic abilities (1-3). Quercetin (QUE) is one such dietary 
polyphenol, commonly found in fruits and vegetables like apples, berries and onions. More 
precisely, QUE belongs to the flavonoid class (4, 5). It has been shown to exert multiple 
pharmacological effects, such as scavenging of oxygen radicals, prevention of lipid peroxidation, 
chelation of transition metals, and inhibition of inflammation (4, 6-9). This high anti-radical/anti-
oxidant activity has been attributed to the presence of three active functional groups in QUE 
structure (Fig. 1): the ortho-dihydroxy (catechol) moiety in the B ring, the C2–C3 double bond in 
conjunction with a 4-oxo function and the hydroxyl substitution at positions 3, 5 and 7 (10, 11). The 
abovementioned beneficial effects, coupled with its safety profile and natural origin, make QUE a 
very attractive candidate for incorporation into formulations intended for skin delivery. However, 
despite the demonstrated safety and efficacy of QUE, its use is hampered by poor water solubility 
and low skin permeability (9, 12). Various strategies have been attempted to improve QUE 
permeability through the skin with the aim of facilitating topical/transdermal delivery, which 
include the synthesis of ester prodrugs (13), microemulsion-based approaches (6, 14), lecithin-
chitosan nanoparticles (12), nanostructured lipid carriers and solid lipid nanoparticles (8, 9, 15). 
Most of these studies have shown some degree of QUE permeation into the skin, but no transdermal 
delivery. We have recently formulated QUE in PEVs, phospholipid vesicles prepared with four 
different hydrophilic penetration enhancers (PEs), essential to improve QUE solubility in water 
thanks to their high solubilizing power: Transcutol® P, propylene glycol, polyethylene glycol 400 
and Labrasol®. All PEVs promoted QUE deposition in the three main skin strata (i.e., stratum 
corneum, epidermis and dermis) and transdermal permeation (4). Hence, it is apparent that the 
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development of lipid-based nanosystems capable of transporting QUE across the skin is of great 
significance. In order to ascertain whether topically applied QUE in PEVs was actually able to exert 
its bioactivity in coping with oxidative stress and inflammation, in vivo tests were conducted and 
are presented in this paper. PEVs were prepared using polyethylene glycol 400, and their physico-
chemical features (i.e., size distribution, surface charge, entrapment efficiency) and lamellar 
assembly probed. Their efficacy and safety in skin delivery were assessed by testing their activity 
against common inflammatory endpoints in mice: inhibition of chemically-induced oedema and 
leukocyte infiltration (reflected in myeloperoxidase –MPO– activity). The confocal imaging of the 
treated skin was also performed. In addition, the in vitro uptake and distribution of QUE-loaded 
vesicles in 3T3 dermal fibroblasts were evaluated. 
 
MATERIALS AND METHODS 
Materials 
Lipoid S75 (S75), soybean lecithin with 70% phosphatidylcholine (and ~10% 
phosphatidylethanolamine, lysophosphatidylcholine 3% maximum, triglycerides 3% maximum, 
fatty acids 0.5% maximum, tocopherol 0.1-0.2%) was purchased from Lipoid GmbH 
(Ludwigshafen, Germany). Quercetin (QUE, 3,3′,4′,5,7-pentahydroxyflavone; ≥95% pure), 
phosphate buffer solution (PBS, pH 7.4) and polyethylene glycol 400 (PEG) were purchased from 
Sigma-Aldrich (Milan, Italy). 12-O-Tetradecanoylphorbol 13-acetate (TPA) and all other reagents, 
if not otherwise specified, were from Sigma (Madrid, Spain). 
 
Quercetin solubility 
QUE solubility was assessed by dispersing an excess amount of the drug in 5 ml of PBS or 
PEG/PBS mixtures (5%, 10% v/v). Dispersions were kept under constant stirring for 24 h at 25 °C 
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in a thermostated bath. After QUE excess sedimentation (18 h), the clear solutions were centrifuged 
for 10 minutes at 10000 rpm and the supernatant analyzed by HPLC as described elsewhere (4). 
 
Vesicle preparation 
QUE and S75 were weighed in a glass vial and left hydrating overnight in PBS, or a mixture of 
PEG/PBS (5%, 10% v/v), to obtain liposomes and PEVs, respectively (Table I). The suspensions 
were sonicated (5 seconds on and 2 seconds off, 100 cycles; 13 µm of probe amplitude) with a 
Soniprep 150 (MSE Crowley, London, UK). Empty liposomes and PEVs were also prepared. 
 
Vesicle characterization 
Vesicle formation and morphology were checked by cryogenic transmission electron microscopy 
(cryo-TEM). For the analysis, a thin aqueous film was formed by placing 5 µl of the vesicular 
dispersion on a glow-discharged holey carbon grid, and then blotting the grid against filter paper. 
The resulting thin sample film spanning the grid holes were vitrified by plunging the grid (kept at 
100% humidity and room temperature) into ethane, maintained at its melting point with liquid 
nitrogen, using a Vitrobot (FEI Company, Eindhoven, The Netherlands). The vitreous film was 
transferred to a Tecnai F20 TEM (FEI Company, Eindhoven, The Netherlands) using a Gatan cryo-
transfer (Gatan, Pleasanton, CA), and the sample was observed in a low-dose mode. Images were 
acquired at 200 kV at a temperature of –170/–175 °C, using low-dose imaging conditions not 
exceeding 20 e–/Å2, with a 4096 × 4096 pixel CCD Eagle camera (FEI Company, Eindhoven, The 
Netherlands). 
The average diameter, polydispersity index (P.I., a measure of the width of size distribution) and 
zeta potential of vesicles were determined by Dynamic and Electrophoretic Light Scattering using a 
Zetasizer nano-ZS (Malvern Instruments, Worcestershire, UK). Samples (n = 3) were diluted 
(1:100) with PBS, or PEG/PBS (5%, 10% v/v) when appropriate, and analysed at 25 °C. 
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Vesicles were purified from the non-incorporated drug by dialysis. Each sample (1 ml) was loaded into 
Spectra/Por® tubing (12–14 kDa MW cut-off; Spectrum Laboratories Inc., DG Breda, The 
Netherlands) and dialyzed against PBS (2 L), or PEG/PBS (5%, 10% v/v) when appropriate, which 
was refreshed every hour during 4 hours, at 5 °C. Drug entrapment efficiency (EE%), expressed as 
the percentage of the amount of drug initially used, was determined by HPLC after disruption of 
unpurified and purified vesicles with 0.025% Triton X-100. QUE content was assayed as described 
elsewhere (4). 
The lipid content of the vesicle dispersions was assessed by the Stewart assay (16). Briefly, an 
aliquot of liposome and PEV suspension was added to a biphasic mixture of aqueous ammonium 
ferrithiocyanate solution (0.1 N) and chloroform. The concentration of S75 was obtained by 
measuring the absorbance at 485 nm into the organic phase. The aggregation efficiency (AE%) 
represented the effective amount of aggregated phospholipids expressed as the percentage of the 
amount initially used. 
 
X-ray diffraction 
Vesicle structure was studied by Small and Wide-Angle X-ray Scattering (SWAXS). SAXS and 
WAXS patterns were recorded simultaneously using a S3-MICRO (Hecus X-ray systems, Graz, 
Austria) coupled to a GENIX-Fox 3D X-ray source (Xenocs, Grenoble, France) working at 50 Kv 
and 1 mA. This source produces a focused X-ray beam with λ = 1.542 Å at Cu Kα-line with more 
than 97% purity and less than 0.3% Kβ. The two detectors are position sensitive detectors PSD 50 
(Hecus, Graz, Austria). The working q-range were 0.01 ≤ q ≤ 0.6 Å−1, in the small angle, and 2.8 ≤ 
q ≤ 3.5 Å−1 in the wide angle range, where q = (4 π sin θ)/λ is the modulus of the scattering wave 
vector, θ the scattering angle and λ the wavelength. The vesicular dispersions were loaded into glass 
capillaries and the diffraction patterns were recorded at 25 °C. All the scattering curves were 
reproduced twice, with subsequent calculation of the electron distance distribution, and yielded 
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identical results. For the figures, a representative curve was selected, plotting the scattering intensity 
I as a function of the scattering vector q. SAXS patterns were analyzed using the MCG model 
developed by Pabst et al. (17). The analysis technique models the full q-range in the SAXS regime, 
including Bragg peaks and diffuse scattering. The bilayer electronic density profile is calculated as 
the sum of three gaussians, one corresponding to the methyl contributions and the other two 
corresponding to the polar heads. Differently from the model by Pabst et al. (17), we also included a 
constant term through the hydrophobic part of the bilayer to give account of the methylene 
contribution. The interbilayer ordering is taken into account considering the modified Caillé model 
as in the work by Pabst et al. (17). By this procedure, relevant structural parameters, as well as the 
distribution of electron density in the polar and apolar regions of membranes, were obtained. The 
model allowed fitting the SAXS pattern of bilayer-based structures, i.e. vesicles and lamellar 
phases. From the analysis, the membrane thickness was obtained through the definition db = 2 (Zh + 
fwhm / 2), where Zh is the distance to the center of the bilayer of the polar head Gaussian with the 
corresponding full-width at half maximum fwhm. To derive the other parameters, we used 159.0 
electrons for the polar head and 261.9 electrons for the hydrophobic tails (based on the composition 
of S75). The electron density of the medium with different concentrations of PEG slightly differed 
from that of water. Hence, we kept the water level as a reference throughout, this having no effect 
on the fitting. 
 
Mice and in vivo experimental design 
Female CD-1 mice (5-6 weeks old, 25-35 g) were obtained from Harlan Laboratories (S. Pietro al 
Natisone, Italy) and acclimatized for 1 week before use. Animals were fed rodent pellets (Global 
diet 2014, Harlan Teklad, Barcelona, Spain) ad libitum with free access to water, and maintained at 
20 ± 2 ºC with a relative humidity of 60 ± 5% and a 12-h light/dark cycle. All studies were 
performed in accordance with European Union regulations for handling and use of laboratory 
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animals. Protocols were approved by the Institutional Animal Care and Use Committee of the 
University of Valencia. 
The back skin of mice (n = 4 per group) was shaved one day before the experiment, and those 
animals showing no hair re-growth were used. TPA dissolved in acetone (243 µM; 3 µg/20 µl) was 
applied to the shaved dorsal area (approximately 2 cm2) to induce cutaneous inflammation (day 1). 
Negative control mice received acetone only (20 µl). Empty or QUE-loaded vesicles, and QUE in a 
PEG/PBS mixture (10% v/v), were applied dropwise (20 µl) and carefully smeared over the same 
dorsal site 3 h after TPA application (non-occlusive conditions), until complete absorption. The 
procedure was repeated (at 24-h intervals) on day 2 and 3. On day 4, mice were sacrificed by 
cervical dislocation. 
 
Oedema formation and myeloperoxidase determination 
The inhibitory effect of vesicular QUE on TPA-induced inflammation was evaluated by two 
biomarkers: oedema formation and MPO activity. Mice were sacrificed after 72 hours of treatment 
(on day 4). The treated dorsal skin area of each mouse was excised and weighted to assess any 
increase indicative of oedema formation, and immediately stored at -80 ºC (18, 19). 
MPO assay was performed following the methods of De Young et al. (20) and Sato et al. (21), 
adapted to a 96-well plate format, as previously reported (19). Briefly, skin biopsies were 
homogenized and centrifuged. The supernatant was incubated with hydrogen peroxide and 
tetramethylbenzidine and then assayed for MPO activity spectrophotometrycally at 620 nm. The 
MPO activity was calculated from the linear portion of a standard curve. 
 
Confocal Laser Scanning Microscopy of mouse skin 
Confocal laser scanning microscopy (CLSM) was employed to examine the architecture, 
ultrastructure and potential wound healing of treated mouse skin. Mice were sacrificed after 72 
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hours of treatment (on day 4). The treated dorsal skin area of each mouse was excised and rapidly 
frozen at -80 °C. Sections of skin (7 µm thickness) were cut with a cryostat (Leica CM1950, 
Barcelona, Spain) orthogonally (in the z axis) to the surface, and examined under a FluoView 
FV1000 inverted confocal microscope (Olympus, Barcelona, Spain) equipped with a 
Ultraviolet/Visible light laser. Using a UPlanSApo 20x objective NA 0.75, images with a field size 
of 1024 × 1024 µm were generated. 
 
Cell culture and treatment with colloidal dispersions 
3T3 mouse fibroblasts (ATCC collection) were grown as adherent cultures in phenol red-free 
Dulbecco’s Modified Eagle’s medium (DMEM) with high glucose, supplemented with 10% (v/v) 
fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 µg/ml) (Life Technologies, 
Monza, Italy), and incubated at 37 °C in a humidified atmosphere of 5% CO2. 
Cellular uptake of the testing formulations was investigated by CLSM using vesicles labelled with 
fluorescent rhodamine (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl); Avanti Polar Lipids, Alabama), and loaded with fluorescent QUE. 3T3 cells were grown 
to confluence in 35-mm dishes and then incubated with rhodamine-labelled, QUE-loaded vesicles 
for 30 minutes, 2 and 4 hours. For the observation under the FluoView FV1000 confocal 
microscope, cells were fixed with 4% paraformaldehyde and stained with the blue-fluorescent DNA 
stain Hoechst 33258 (Sigma-Aldrich, Milan, Italy) to visualize the cell nucleus, and green 
phalloidin fluorescein-isothiocyanate for the actin cytoskeleton. 
Pictures were taken in z-stacks using the 60x objective. 
 
Statistical analysis of data 
Results are expressed as the mean ± standard deviation. Parametric and non-parametric analysis of 
variance (ANOVA and Kruskal-Wallis, respectively) and Bartlet’s test for homogeneity of variance 
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were performed using SPSS version 17.0 for Windows (SPSS Inc., USA). Post hoc testing (P<0.05) 
for multiple comparisons was performed by Scheffe and Dunnett’s T3 tests. 
 
RESULTS 
Vesicle characterization: physico-chemical and structural features 
Light Scattering results, summarized in Table II, show an increase (P<0.05) in the average diameter 
of the prepared vesicles, as a function of the presence of loaded QUE and PEG (the higher its 
concentration, the larger the vesicles). Nevertheless, the vesicles were small in size, between 100 
and 150 nm, with acceptable and repeatable homogeneity (P.I. ≤0.35), and zeta potential values 
slightly negative (-10 mV), due to the low charge carried by S75. PEG-PEVs loading QUE were 
previously prepared, but they differed in composition: a different commercial mixture of 
phospholipids, Phopholipon®50 (P50; containing 45% phosphatidylcholine, 10–18% 
phosphatidylethanolamine, 37% polar lipids, and 3% triglycerides), was used, at a 3-fold lower 
concentration (60 mg/ml); PEG was mixed with water at a much higher concentration (40% v/v); 
QUE concentration was 5-fold lower (2 mg/ml). Vesicles of approximately 190 nm in diameter 
were obtained, with a P.I. ≈ 0.3 and zeta potential around -50 mV. Such higher surface charge is 
attributable to the different phospholipid mixture in the different dispersion medium. Interestingly, 
the formulations presented in this work disclose similar features, despite loading a higher amount of 
QUE and containing a lower amount of PEG. The presence of PEG increased both drug solubility 
(by 3.5- and 5.1-fold with 5% and 10% PEG, respectively; Table III) and the entrapment efficiency 
of vesicles. This was especially true in the case of 5%PEG-PEVs: 75% vs 52% for liposomes 
(Table II). 
According to aggregation efficiency data from Stewart assay, around 70% of phospholipids (Table 
II) were aggregated to form vesicles. 
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Cryo-TEM observations confirmed the formation of small and fairly spherical vesicles, with 
different lamellarity, directly proportional to PEG content. There was no evidence of free QUE 
crystals. Figure 2 illustrates a heterogeneous population of concentric oligolamellar and 
multilamellar structures of approximately 150 nm in diameter, a value consistent with those 
determined by size measurements. Some invaginated vesicles were present, probably due to the 
occurrence of ionic gradients during sample processing. 
Further insight into vesicle morphology and lamellar arrangement were gained by SAXS and 
WAXS, well-established techniques for the study of self-assembling nanostructures. The SAXS 
experimental data were fitted to a bilayer model with interbilayer correlations (see the experimental 
part for details). In Figure 3 the resulting fits are shown as lines. The reduced χ2 (χ2 = 1 for purely 
statistical noise) values were below 2, indicative of nearly perfect fitting. 
Figure 3A shows the scattering patterns of liposomes and PEVs with different PEG content, 
together with the best fits of the modified Caillé model. It is apparent that the higher the PEG 
content, the better defined the correlation peaks are. This implies an increase in the number of 
correlated bilayers (N) and an increase in bilayer rigidity, typical of multilamellar vesicles, as 
reflected in the values of the fitted parameters listed in Table IV. The marked reduction of the Caillé 
parameter (η) and the increase in the number of correlated lamellae (N) are related to the increase in 
bilayer stiffness. Some displacements of the scattering peaks to higher q values are also evident, 
resulting in an overall reduction of the repetition distance (d), as PEG content increased. Getting in 
the details of the fittings, it can be observed that this reduction of the repetition distance is governed 
mainly by the reduction of the water layer thickness (dw), while the rest of the parameters (dc, db and 
Zh) show variations within the fitting uncertainty. 
Comparing Figure 3B with Figure 3A and the relative fitting parameters, it can be inferred that the 
effect of QUE on the scattering patterns is marginal, and consequently on the bilayer characteristics, 
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if compared to that of PEG. Nevertheless, in QUE-loaded vesicles (Figure 3B) the diffraction peaks 
are sharper, indicating a disordering effect caused by the drug. 
As expected, WAXS spectra (data not reported) exhibited a broad band centered at 18 nm-1, typical 
of the liquid crystalline Lα state of the bilayer. There were no significant differences among the 
samples, for either empty or QUE-loaded vesicles. 
 
In vivo inflammatory response 
TPA-induced inflammation in mice is one of the most commonly used models of inflammation for 
evaluating drug anti-inflammatory activity. The topical application of TPA stimulates inflammatory 
reactions that are mediated by leukocyte infiltration. An early hallmark of skin irritation and local 
inflammation is thickening within 1–4 hours due to increased vascular permeability, oedema and 
swelling in the dermis. Then, leukocytes migrate to the dermis within about 24 h, and release MPO, 
a marker enzyme of neutrophil granules, which can be a gauge of neutrophil activation (19). In the 
present study, the weight of treated skin was measured as a parameter of oedema, and MPO as an 
index of inflammatory cell proliferation. 
Topically applied liposomes and PEVs, empty and loaded with QUE, were tested for anti-
inflammatory efficacy, in comparison with a drug dispersion. When viewed macroscopically, TPA-
exposed skin appeared irritated, reddened, scaly and crusted (Figure 4). On the other hand, a 
remarkable amelioration of TPA damage was observed upon administration of QUE-loaded 
vesicles, especially 5%PEG-PEVs: the skin was less dry and the irritation superficial (Figure 4). 
Results from oedema and MPO tests confirmed these observations. TPA-induced oedema was 
reduced by QUE vesicle formulations (~ 1.7-fold, P<0.05; Figure 5), which were also effective in 
inhibiting MPO activity (Figure 5). QUE-loaded liposomes and 10%PEG-PEVs provided a 2.5-fold 
decrease (P<0.05) in MPO, while with 5%PEG-PEVs a 4.7-fold decrease (P<0.01) was achieved. 
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Confocal imaging of mouse treated skin 
Ultrastructural studies of TPA-exposed skin revealed altered epidermal tissue architecture and 
major alterations in dermal connective tissue, characterized by damaged and severely disorganized 
collagen fibers (Figure 6 B). When the supporting connective tissue becomes disorganized and 
loosely arranged, the skin loses its flexibility, strength and firmness. On the contrary, when the 
vesicular formulations containing QUE were administered, the skin featured healing processes 
involving an abnormally large number of collagen fibers and amorphous ground substance, 
produced to repair the damage done to the dermis by TPA. Such tissue regeneration was particularly 
evident in the skin treated with QUE-loaded 5%PEG-PEVs (Figure 6 C). 
 
Cellular uptake of vesicles 
The internalisation of vesicles by 3T3 cells was studied by confocal microscopy. To this purpose, 
fibroblasts were incubated for 30 minutes, 2 and 4 hours with liposomes and PEVs labelled with 
red-fluorescent rhodamine and loaded with QUE, a fluorescent molecule. After 30 minutes, vesicles 
were spread into the cytoplasm, as indicated by the orange fluorescence due to the merging of red-
rhodamine and yellow-QUE (Figure 7). In liposome-exposed cells, the red fluorescence tended to 
progressively disappear after 2 and 4 hours, while the opposite phenomenon occurred when PEVs 
were used: an intense reddish fluorescence was observed, especially after 4 hours of treatment with 
both PEVs (Figure 7). Hence, a massive distribution of vesicular QUE can be concluded. 
 
DISCUSSION 
The present paper reports the development of lipid-based nanovesicles for the loading and skin 
delivery of QUE. Liposomes and PEVs with favourable physico-chemical and morphological 
features were obtained. All vesicles were small in size, spherical in shape and with high drug 
entrapment efficiency, especially PEVs, most likely due to the high solubilising power of PEG. 
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PEG is a pharmaceutically accepted cosolvent that works by reducing the interfacial tension 
between water and a hydrophobic drug. Being its structure H-(O-CH2-CH2)n-OH, where n is 
approximately 8 to 9, PEG has hydrophilic hydrogen-bonding groups that ensure water miscibility, 
and hydrophobic hydrocarbon regions that interfere with water self-association by disrupting its 
hydrogen bonding network. This creates a less-polar environment that results in more lipophilic 
drug molecules going into solution. Accordingly, PEG-PEVs yielded a much higher loading of 
lipophilic QUE than liposomes. 
Thanks to its solubilising ability, PEG was able to modify vesicle packing and features, as revealed 
by Cryo-TEM and SWAXS. These techniques were employed to gain thorough structural and 
dynamical information about the vesicles and their interactions with host molecules (i.e., QUE and 
PEG). SAXS profiles displayed a strong dependence of vesicle lamellarity on the presence and 
concentration of PEG (0%, 5%, 10%). Being PEG highly hydrophilic, it strongly interacts with the 
interlamellar water layers and the polar regions of phospholipids, thus affecting the overall vesicular 
structure. This alters the bilayer microstructure, with consequent changes (i.e., increase) in the 
number of correlated lamellae and their rigidity. With the increasing concentration of PEG, the 
SAXS reflections became more intensive and narrower, a finding clearly indicating increasing 
ordering, thus a multilamellar organization. In the light of these findings, it can be concluded that 
liposomes consisted of a heterogeneous population of unilamellar and oligolamellar vesicles, while 
PEVs were predominantly or uniquely multilamellar, as PEG content increased (i.e., 5% and 10%, 
respectively). It is noteworthy that QUE showed a marginal disordering effect on the structure of 
both liposome and PEV bilayers, with respect to PEG, most likely due to the localization at the 
bilayer-water interface. The water layer thickness increased upon drug incorporation (dw from 2.9 to 
3.0 in liposomes, from 1.9 to 2.2 in 5%PEG-PEVs). This increase was accompanied by a small 
decrease in db, which is not due to a decrease in dc. This may be congruent with QUE getting in the 
lipid-water interface, and may also explain the increase in bilayer rigidity (decrease of Caillé 
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parameter). On the other hand, in PEVs, QUE locates at the bilayer-water interface as well as in the 
water phase, because water-miscible PEG favors the solubilization of the drug in the aqueous 
dispersion. 
The results of vesicle lamellarity obtained by SAXS were in full agreement with Cryo-TEM 
examination, which also corroborated size measurements by Light Scattering, as vesicles larger than 
100 nm were shown. 
The anti-inflammatory potential of QUE in liposomes and PEVs was evaluated in vivo. Our data 
from a previous work established that chemically-induced inflammation on the skin was at a 
maximum after 72 hours of TPA exposure (19). TPA application elicits a series of reactions, 
namely inflammation and oxidative stress, that can be gauged by oedema formation and MPO 
activity. It was found that QUE decreased inflammation of the skin by reducing irritation, oedema 
and leukocyte accumulation. Further, as highlighted by confocal imaging, QUE triggered tissue 
regeneration by stimulating new tighter collagen fibers to grow and the production of ground 
substance, in order to restore the skin architecture disorganized by TPA. These remarkable benefits 
provided by nanoentrapped QUE, especially when delivered by 5%PEG-PEVs, were supposed to be 
due to a synergistic mechanism between PEG and the vesicles. PEG improves vesicular bilayer 
fluidity and also reduces the stratum corneum barrier function transiently, thus creating an easier 
pathway for the highly fluidized vesicles (22-24). PEVs can enter intact (at least partially) the 
stratum corneum with the loaded QUE, and diffuse down to the epidermis and dermis. Here, they 
come into contact with fibroblasts and facilitate drug uptake, allowing it to exert its anti-
inflammatory/antioxidant activity where necessary (i.e., the dermis mainly). Interestingly, in vivo 
studies provided evidence that topically applied QUE, when delivered by 5%PEG-PEVs, was more 
effective than previously tested diclofenac in PEVs at the same dose (10 mg/ml), under the same 
conditions (19). The major effect was on MPO activity: with QUE-loaded 5%PEG-PEVs a 4.7-fold 
decrease was achieved, versus a 2.7-fold with diclofenac-loaded PEVs. Therefore, it can be deduced 
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that natural QUE, in the appropriate formulation, possesses a superior efficacy in counteracting the 
inflammatory responses provoked by TPA on the skin. Inflammation is a multifactorial process 
involving the release of MPO from neutrophils and monocytes, which leads to the generation of 
reactive oxygen species (ROS) implicated in skin damage. The superior efficacy of QUE over 
diclofenac is reasonably due to its dual action: coping with ROS and increasing fibroblast 
proliferation. Fibroblasts are found within the dermis and are responsible for the synthesis of 
collagen, glycoproteins, glycosaminoglycans and other elements of the extracellular matrix of the 
connective tissue, which provides mechanical support to skin. Hence, dermal fibroblasts play a key 
role in wound healing: without them, the wound site could not regenerate extracellular matrix and 
epidermis skin cells could not proliferate over the wound site, and the skin could not properly 
recover from injury. In vitro studies showed that QUE-loaded PEVs were able to easily enter the 
fibroblasts and massively diffuse in the cytoplasm, at least for 4 hours, thus allowing QUE to exert 
its actions. Conversely, liposomes were rapidly internalized into the cell interior, where their 
content is released subsequent to vesicle degradation by lysosomal and endosomal enzymes. This 
different behaviour explains the higher efficacy of PEVs to carry and localize QUE in the site of 
inflammation. 
 
CONCLUSIONS 
A comprehensive characterization of nanovesicular systems for the loading and skin delivery of 
QUE was carried out. In vivo results indicated that vesicles, and especially PEVs, were capable of 
localizing the drug in the site of inflammation, that is the dermis, inhibiting oxidative stress and 
leukocyte accumulation and stimulating the repair of skin damage induced by TPA. The actual 
entry and diffusion in dermal fibroblasts was demonstrated in vitro. In conclusion, this work shows 
the interesting potential of vesicular systems, particularly PEVs, in the treatment of inflammatory 
skin disorders. 
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FIGURES 
 
Fig. 1. Chemical structure of quercetin. 
 
Fig. 2. Cryo-TEM image of quercetin-loaded 5%PEG-PEVs. 
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Fig. 3. SAXS patterns of empty and quercetin-loaded liposomes and PEVs. 
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Fig. 4. Photographs of dorsal skin of mice: untreated, treated with TPA-only to induce 
inflammation, treated with TPA followed by the administration of quercetin-loaded 5%PEG-PEVs. 
 
 
Fig. 5. Skin oedema index (skin biopsy/body weight ratio) and MPO activity of mice with TPA-
induced inflammation, after treatment with testing samples, compared with TPA-only treated mice 
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(positive control) and acetone receiving mice (negative control). Each bar is the mean ± S.D. of four 
animals (statistical significant difference P * < 0.05, P ** < 0.01, compared to TPA). 
 
Fig. 6. Confocal cross-sectional images of mouse skin after 72 h of treatment with TPA-only (B), or 
TPA followed by the administration of quercetin-loaded 5%PEG-PEVs (C), compared to untreated 
healthy skin (A). Skin autofluorescence is shown in red. 
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Fig. 7. 3T3 fibroblasts with blue-stained nuclei and yellow-stained actin cytoskeleton showing the 
progressive increase in red and yellow fluorescence as rhodamine-labelled vesicles loaded with 
fluorescent quercetin diffuse in the cytoplasm following a 30 minute-, 2h- and 4 h-exposure to 
liposomes and PEVs. 
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TABLES 
 
Table I Composition of Vesicular Formulations 
Component Liposomes 5%PEG-PEVs 10%PEG-PEVs 
S75 180 mg 180 mg 180 mg 
QUE 10 mg 10 mg 10 mg 
PEG  0.05 ml 0.1 ml 
PBS 1 ml 0.95 ml 0.9 ml 
 
Table II Characteristics of Empty and Quercetin-Loaded Vesicular Formulations: Mean Diameter, 
Polydispersity Index (P.I.), Zeta Potential (ζ), Entrapment Efficiency (EE%) and Aggregation 
Efficiency (AE%). Values are the Means ± Standard Deviation (n=3) 
 
Sample  Mean diameter 
(nm) 
P.I. ζ (mV) EE% AE% 
 
Liposomes Empty 96±2.4 0.22 −9±0.5 
 
  
QUE 116±5.3 0.35 −9±0.4 52±4.4 74±4.6 
 
5%PEG-
PEVs 
Empty 117±5.7 0.23 −10±0.8 
 
  
QUE 152±2.4 0.34 −10±0.8 75±3.0 71±2.7 
 
10%PEG-
PEVs 
Empty 136±2.6 0.23 −9±0.8 
 
  
QUE 148±3.5 0.31 −10±0.7 60±0.8 73±6.3 
 
 
Table III QUE Solubility in PBS or PEG/PBS Blends (5%, 10% v/v). Values are the Means ± 
Standard Deviation (n=3) 
 
Medium QUE (µg/ml) 
 
PBS 9.3±0.11 
5%PEG in PBS 32.7±5.37 
10%PEG in PBS 47.5±5.20 
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Table IV Selected Fitting Parameters and Derived Parameters for the SAXS Curves of Liposomes 
and PEVs. All Distances are Given in nm. d, Repetition Distance; η, Caillé Parameter; N, Number 
of Correlated Lamellae; σh, Polar Head Amplitude; σc, Methyl Amplitude; Zh, Polar Head Distance 
to the Center of the Bilayer; dc, Hydrophobic Chains Layer Half-Thickness; db, Bilayer Thickness; 
dw, Water Layer Thickness 
 
 Empty 
liposomes 
Empty 
5%PEG-
PEVs 
Empty 
10%PEG-
PEVs 
QUE 
liposomes 
QUE 
5%PEG-
PEVs 
QUE 
10%PEG-
PEVs 
d  6.94±0.5 5.94±0.1 5.60±0.05 6.99±0.5 6.03±0.1 5.69±0.05 
η 0.38±0.2 0.080±0.010 0.038±0.005 0.31±0.2 0.16±0.02 0.012±0.002 
N
 
1.5±0.3 2.5±0.3 3.5±0.2 1.5±0.3 2.5±0.3 3.5±0.2 
σh
 
0.32±0.01 0.36±0.01 0.37±0.01 0.31±0.01 0.28±0.01 0.34±0.01 
σc
 
0.24±0.01 0.20±0.01 0.19±0.01 0.25±0.01 0.17±0.01 0.25±0.01 
Zh   1.63±0.02 1.62±0.02 1.56±0.01 1.61±0.02 1.57±0.02 1.63±0.01 
dc            1.26±0.02 1.20±0.02 1.12±0.02 1.24±0.02 1.24±0.02 1.24±0.02 
dB             4.02±0.05 4.07±0.05 4.00±0.05 3.96±0.05 3.81±0.05 4.07±0.05 
dw            2.9±0.5 1.9±0.1 1.6±0.1 3.0±0.5 2.2±0.1 1.6±0.1 
 
